Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

A. Chiappella, M. Martelli, E. Angelucci, E. Brusamolino, A. Evangelista, A.M. Carella, C. Stelitano, G. Rossi, M. Balzarotti, F. Merli, G. Gaidano, V. Pavone, L. Rigacci, F. Zaja, A. D'Arco, N. Cascavilla, E. Russo, A. Castellino, M. Gotti, A.G. CongiuM.G. Cabras, A. Tucci, C. Agostinelli, G. Ciccone, S.A. Pileri, U. Vitolo

Research output: Contribution to journalArticle

28 Citations (Scopus)
Original languageEnglish
Pages (from-to)1076-1088
Number of pages13
JournalThe Lancet Oncology
Volume18
Issue number8
DOIs
Publication statusPublished - 2017

Cite this

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. / Chiappella, A.; Martelli, M.; Angelucci, E.; Brusamolino, E.; Evangelista, A.; Carella, A.M.; Stelitano, C.; Rossi, G.; Balzarotti, M.; Merli, F.; Gaidano, G.; Pavone, V.; Rigacci, L.; Zaja, F.; D'Arco, A.; Cascavilla, N.; Russo, E.; Castellino, A.; Gotti, M.; Congiu, A.G.; Cabras, M.G.; Tucci, A.; Agostinelli, C.; Ciccone, G.; Pileri, S.A.; Vitolo, U.

In: The Lancet Oncology, Vol. 18, No. 8, 2017, p. 1076-1088.

Research output: Contribution to journalArticle

Chiappella, A. ; Martelli, M. ; Angelucci, E. ; Brusamolino, E. ; Evangelista, A. ; Carella, A.M. ; Stelitano, C. ; Rossi, G. ; Balzarotti, M. ; Merli, F. ; Gaidano, G. ; Pavone, V. ; Rigacci, L. ; Zaja, F. ; D'Arco, A. ; Cascavilla, N. ; Russo, E. ; Castellino, A. ; Gotti, M. ; Congiu, A.G. ; Cabras, M.G. ; Tucci, A. ; Agostinelli, C. ; Ciccone, G. ; Pileri, S.A. ; Vitolo, U. / Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. In: The Lancet Oncology. 2017 ; Vol. 18, No. 8. pp. 1076-1088.
@article{6e8fd7505ec84efd9bb54ab16e2d2448,
title = "Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study",
author = "A. Chiappella and M. Martelli and E. Angelucci and E. Brusamolino and A. Evangelista and A.M. Carella and C. Stelitano and G. Rossi and M. Balzarotti and F. Merli and G. Gaidano and V. Pavone and L. Rigacci and F. Zaja and A. D'Arco and N. Cascavilla and E. Russo and A. Castellino and M. Gotti and A.G. Congiu and M.G. Cabras and A. Tucci and C. Agostinelli and G. Ciccone and S.A. Pileri and U. Vitolo",
note = "Cited By :4 Export Date: 2 March 2018",
year = "2017",
doi = "10.1016/S1470-2045(17)30444-8",
language = "English",
volume = "18",
pages = "1076--1088",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "8",

}

TY - JOUR

T1 - Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

AU - Chiappella, A.

AU - Martelli, M.

AU - Angelucci, E.

AU - Brusamolino, E.

AU - Evangelista, A.

AU - Carella, A.M.

AU - Stelitano, C.

AU - Rossi, G.

AU - Balzarotti, M.

AU - Merli, F.

AU - Gaidano, G.

AU - Pavone, V.

AU - Rigacci, L.

AU - Zaja, F.

AU - D'Arco, A.

AU - Cascavilla, N.

AU - Russo, E.

AU - Castellino, A.

AU - Gotti, M.

AU - Congiu, A.G.

AU - Cabras, M.G.

AU - Tucci, A.

AU - Agostinelli, C.

AU - Ciccone, G.

AU - Pileri, S.A.

AU - Vitolo, U.

N1 - Cited By :4 Export Date: 2 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/S1470-2045(17)30444-8

DO - 10.1016/S1470-2045(17)30444-8

M3 - Article

VL - 18

SP - 1076

EP - 1088

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -